Stathmin (SP49) Rabbit Monoclonal Antibody
SIGMA/394R-1
Product Type: Chemical
Immunohistochemistry Stathmin (SP49) on cervix tissue
| antibody form | culture supernatant |
| antibody product type | primary antibodies |
| biological source | rabbit |
| clone | SP49, monoclonal |
| conjugate | unconjugated |
| control | cervical intraepithelial neoplasia – high grade, tonsil |
| description | For In Vitro Diagnostic Use in Select Regions (See Chart) |
| form | buffered aqueous solution |
| isotype | IgG |
| manufacturer/tradename | Cell Marque® |
| packaging | bottle of 1.0 mL predilute (394R-17) |
| bottle of 7.0 mL predilute (394R-18) | |
| vial of 0.1 mL concentrate (394R-14) | |
| vial of 0.5 mL concentrate (394R-15) | |
| vial of 1.0 mL concentrate (394R-16) | |
| Quality Level | 100  |
| 500 |
|
| shipped in | wet ice |
| species reactivity | human |
| storage temp. | 2-8°C |
| technique(s) | immunohistochemistry (formalin-fixed, paraffin-embedded sections): 1:25-1:100 |
| visualization | cytoplasmic |
| Analysis Note: |
|
||||
| General description: | The distinction between high grade cervical intraepithelial neoplasia (CIN2/3) from low grade cervical intraepithelial neoplasia (CIN1) is clinically significant with treatment recommendations linked specificallyto risk of cancer or CIN3 outcome. CIN1 will progress into invasive carcinoma in <1% of cases and is typically managed with Papanicolaou smear follow-up, whereas CIN2/3 has a 5% to 20% risk of progression1 and is usually treated with an excisional procedure (loop electrosurgical excision procedure or cone biopsy).1 Stathmin, also referred to as Stathmin-1 and oncoprotein18, is a ubiquitous microtubule-destabilizing protein shown to be important during mitosis and has been implicated as a regulator of cell motility and migration. Recent studies show anti-stathmin is positive in 24/82 (29%) CINs with differential expression based on the grade of the lesion as 5/56 (9%) CIN1, 5/11 (45%) CIN2, and 14/15 (93%) CIN3; whereas, anti-p16 staining of the same cases was immuno-reactive in 66/83 (80%) CINs, including 40/56 (71%) CIN1, 11/11 (100%) CIN2, and 15/16 (94%) CIN3. Anti-stathmin shows similar sensitivity for CIN3 to anti-p16 (93% vs 94%) although it drops off for CIN2 (73% vs 96%). The specificity of anti-stathmin for both CIN2/3 (94%) and CIN3 (89%) is higher than that of anti-p16 (44% and 39%, respectively). Anti-Stathmin stains basal layer of normal benign ectocervix. A well-oriented fragment of cervix tissue would increase the accuracy of diagnosis. In conclusion, based on recent studies, anti-stathmin has a higher specificity relative to anti-p16; therefore, anti-stathmin has major potential as a diagnostic marker in CIN classification over anti-p16. |
||||
| Legal Information: | Cell Marque is a registered trademark of Merck KGaA, Darmstadt, Germany | ||||
| Other Notes: | For Technical Service please contact: 800-665-7284 or email: service@cellmarque.com | ||||
| Other Notes: | Stathmin Positive Control Slides, Product No. 394S , are available for immunohistochemistry (formalin-fixed, paraffin-embedded sections). |
||||
| Physical form: | Solution in Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide | ||||
| Preparation Note: | Download the IFU specific to your product lot and format  Note: This requires a keycode which can be found on your packaging or product label. |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 2 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Storage Temp. | 2-8°C |
| UNSPSC | 12352203 |